Glaucoma Market

DelveInsight’s ‘Glaucoma—Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The Glaucoma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glaucoma market size from 2019 to 2032. The Report also covers current Glaucoma treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Geography Covered

  • The United States
  • EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Glaucoma Market Disease Understanding and Treatment Algorithm

Glaucoma Overview

According to the American Academy of Ophthalmology, glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The “angle” in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.

 

Open-angle glaucoma (OAG) is the most common form of the disease. The drainage angle formed by the cornea and iris remains open, but the trabecular meshwork is partially blocked. This causes pressure in the eye to increase gradually and damages the optic nerve. It happens so slowly that the patient may lose vision before they are even aware of a problem, while in the case of narrow-angle glaucoma, the structure inside the eye that allows fluid to drain normally from the eye (called the drainage angle) becomes restricted. Narrow drainage angles in the eye increase the risk of the drainage angle that gets blocked, resulting in a significant increase in eye pressure and risk of vision loss. If this occurs, narrow-angle glaucoma is usually called angle-closure glaucoma.

Continued in the report…..

 

Glaucoma Diagnosis

Although glaucoma is not a curable disease, early diagnosis and adequate treatment are effective in reducing or preventing further optic nerve (ON) damage. The difficulty of distinguishing between eyes without glaucoma and eyes with early or subtle glaucoma is widely acknowledged. Furthermore, there is no unanimous opinion on what constitutes the first signs of damage in glaucoma.

 

Initial Glaucoma Evaluation

The initial glaucoma evaluation may include the tests and procedures of a comprehensive adult eye and vision examination in addition to some procedures specific to the differential diagnosis of glaucoma. Proper management of glaucoma requires a longitudinal evaluation of established baseline data for important clinical parameters.

Continued in the report…..

 

Glaucoma Treatment

Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve.

 

There is no cure for glaucoma, but early treatment can often stop the damage and protect the vision. Doctors use a few different types of treatment for glaucoma, including medicines (usually eye drops), laser treatment, and surgery. 

Continued in the report…..

Glaucoma Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma, Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Glaucoma Key Findings

  • The total diagnosed prevalent population of Glaucoma in the 7MM was 11,048,000 in 2021, which is expected to increase in the forecast period (2022-2032).
  • Among the five European countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,115,113 cases, followed by Italy and France in 2021. On the other hand, Spain had the lowest. 
  • Japan had 3,387,932 diagnosed prevalent cases for Glaucoma in 2021.
  • In 2021, in the United States, open-angle glaucoma was more prominent than closed angle with total cases of 3,119,031 cases of open angle glaucoma. Out of these total open-angle glaucoma cases, 2,807,128 cases were of primary open-angle glaucoma whereas secondary open-angle glaucoma had 311,903 cases in the United States in 2021.
  • There were a total of 273,002 cases of steroid induced glaucoma in Japan in 2021. These cases are anticipated to decrease during the forecast period.
  • Highest number of cases of glaucoma in  the 7MM wre observed in the 40years and above age group with a total of 10,099,987 cases in 2021. The least number of cases were observed in 2 to <18 years of age group. These cases are anticipated to increase during the forecast period.
  • “As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries. The highest proportion of Gluacoma cases was observed in 40 years and above age group in the 7MM. Among the major types of Glaucoma, i.e., open-angle and close-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases”.

 

Glaucoma Market

 

Country-Wise Glaucoma Epidemiology

The epidemiology segment also provides the Glaucoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Glaucoma Emerging Drugs

 

PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)

PDP-716 is a novel, once-a-day formulation of Brimonidine developed using SPARC’s TearActTM Technology for treatment of Glaucoma. The drug provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. The drug contains brimonidine which is one of the most commonly used treatments of glaucoma and ocular hypertension. The company has recently released the topline results for the Phase III clinical trials for PDP-716 in 2021.

Products detail in the report…

 

TC-002 : TearClear

TC-002 is a preservative-free latanoprost ophthalmic solution that is being developed by TearClear for the treatment of glaucoma. TearClear is the first and only company to develop products that deliver preservative-free drops to the eye while maintaining BAK preserved formulations in the bottle.

Products detail in the report…

List to be continued in the report…

 

Glaucoma Market

 

Glaucoma Market Outlook

Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of glaucoma. It develops slowly and sometimes without noticeable sight loss for many years.

 

The damage caused by glaucoma cannot be reversed. But treatment and regular checkups can help slow or prevent vision loss, especially if the disease is in its early stages. Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery or a combination of any of these.

 

Management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. Besides these pharmacological treatment measurements, incisional surgery, laser surgery, and medication are also preferred.

 

There are several risk factors like age > 60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, and myopia), low educational status, smoking, African descent, and visual problems are associated with this indication and treatment pattern varies accordingly.

 

The main goal of glaucoma treatment is to increase the quality of life through the reduction of IOP to preserve visual function. In the process of IOP reduction, an ideal medication should have a schedule that is simple to follow, be least interrupting with a patient’s life, highly tolerable and affordable. However, the medical treatment of glaucoma has associated side effects, complications, and costs.

 

Prostaglandins as a newer class of IOP-reducing agents have gained tremendous popularity in the management of glaucoma. Prostaglandins are biologically active derivatives of arachidonic acid with diverse local responses that are tissue-dependent. Arachidonic acid is bound to phospholipids in the membranes of most mammalian cells. The release of arachidonic acid is catalyzed by the enzyme phospholipase A2, and arachidonic acids are then converted into PGs by cyclooxygenase and PG synthetase. PGs are the most potent ocular hypotensive agents yet discovered.

 

Multiple prostanoid receptors (e.g., DP, EP1 to EP4, FP, IP, and TP) have been identified based on studies using molecular biologic, second-messenger, radio-ligand binding, and functional techniques. In the United States, drugs of this class have been approved in the past few years like Vyzulta, Xelpros, and Travatan Z by the US FDA.

 

After the Initial introduction of prostaglandins in the US in 1996, rapidly replaced topical beta-blockers as first-line IOP-lowering agents, mostly because of their potency, safe systemic side-effect profile, and once-daily dosing.

 

According to the (Glaucoma Research Foundation, n.d.), Prostaglandin analogs are the first treatment choice for many glaucoma patients. A comparative analysis was performed by (Li et al., 2016). In this comparative analysis, randomized controlled trials that compared a single active topical medication with no treatment/placebo or another single topical medication were included. This study concluded that all active first-line drugs are effective compared to placebo and prostaglandins that were more efficacious in lowering IOP at 3 months than beta-blockers, alpha agonists, or carbonic anhydrase. Bimatoprost, latanoprost, and travoprost are among the most efficacious drugs, although the within-class differences were small and may not be clinically meaningful.

Continued in the report…..

 

Glaucoma Key Findings

  • The market size of Glaucoma in the 7MM was estimated to be USD 4,466 million in 2021.
  • The approved therapies considered in the different class are as follows: Prostaglandin analogs: Latanoprost, Travoprost, Bimatoprost, Tafluprost, Latanoprostene Bunod; Beta Blockers: Timolol, Betaxolol; Carbonic anhydrase inhibitors: Dorzolamide, Brinzolamide; Fixed combinations; Alpha-2-selective adrenergic agonists: Brimonidine, Apraclonidine; Others: Osmotic diuretics (Mannitol and Glycerol).
  • Of this, in the 7MM, the majority of the market share is accommodated by Prostaglandin analogs generating USD 2,086 million, followed by Fixed combinations generating USD 768 million while others contributed the least towards the market share, with USD 73 million, in 2021.
  • In 2021, the least revenue generating class for the treatment of glaucoma was selective EP2 receptor agonists, which generated a total revenue of USD 25 million in the 7MM.
  • “Since glaucoma is one the major cause of blindness, hence there is a pressing need for better understanding of pharmacology of the disease, causing the glaucoma pharmaceutical market to evolve. In the past few years, many drugs have been approved for glaucoma or open-angle glaucoma, and apart from that there are numerous pipeline products as well that are under development for Glaucoma.  Products like, Vyzulta, Rhopressa/Rhokiinsa, Rocklatan/Roclanda, Xelpros, and DURYSTA (bimatoprost implant) are some of the potential latest approved products. Talking about there competition with each other, if we see, Vyzulta, Rhopressa/Rhokiinsa, and Rocklatan/Roclanda are all ophthalmic solution, whereas, DURYSTA is the first dissolvable implant approved for glaucoma.“

 

The United States Market Outlook

This section provides the total Glaucoma market size and; market size by therapies in the United States.

 

EU-5 Market Outlook

The total Glaucoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Glaucoma market size and market size by therapies in Japan are provided.

 

Glaucoma Market

 

Glaucoma Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Glaucoma market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Glaucoma market uptake by drugs; patient uptake by therapies; and sales of each drug.  

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Glaucoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

 

Glaucoma Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Glaucoma emerging therapies.

 

Reimbursement Scenario in Glaucoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

Glaucoma Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Glaucoma market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

 

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 4,466 Million in 2021

Key Companies

Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others

 

Scope of the Glaucoma Market Report

  • The report covers the descriptive overview of Glaucoma, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Glaucoma epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Glaucoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Glaucoma market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glaucoma market.

 

Glaucoma Market Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing prevalence, effectiveness of drugs as both mono and combination therapy will positively drive the Glaucoma market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Glaucoma. The launch of emerging therapies will significantly impact the Glaucoma market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Glaucoma Market Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Glaucoma Pipeline Analysis
  • Glaucoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

 

Glaucoma Market Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Glaucoma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

 

Glaucoma Market Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

 

Key Questions

Market Insights:

  • What was the Glaucoma market share (%) distribution in 2021 and how it would look like in 2032?
  • What would be the Glaucoma total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Glaucoma market size during the forecast period (2022–2032)?
  • At what CAGR, the Glaucoma market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Glaucoma market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Glaucoma market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Glaucoma?
  • What is the historical Glaucoma patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Glaucoma at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Glaucoma?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Glaucoma during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Glaucoma along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Glaucoma in the US and Europe?
  • What are the Glaucoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Glaucoma?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Glaucoma?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Glaucoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Glaucoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Glaucoma?
  • What are the 7MM historical and forecasted market of Glaucoma?

 

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving Glaucoma.
  • To understand the future market competition in the Glaucoma market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Glaucoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Glaucoma market.
  • To understand the future market competition in the Glaucoma market.

Frequently Asked Questions

What is the Glaucoma?
Glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The “angle” in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.
Who are the leading companies in the Glaucoma Market Landscape?
Some of the key players of Glaucoma Market includes Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others
What are the key strengths of Glaucoma Market Report?
Key strengths of Glaucoma Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers and Market Barriers.
Which country is expected to account for the most significant prevalent cases for Glaucoma in the 7MM?
The US is expected to account for the highest Glaucoma prevalent cases.

1. Key Insights

2. Report Introduction

3. Glaucoma Market Overview at a Glance

3.1. Market Share (%) Distribution of Glaucoma by class in the 7MM in 2019

3.2. Market Share (%) Distribution of Glaucoma by class in the 7MM in 2032

4. Executive Summary of Glaucoma

4.1. Treatment landscape of Glaucoma

5. Disease Background and Overview

5.1. Introduction

5.2. Classification of Glaucoma

5.2.1. Classification of Open-Angle Glaucoma (OAG)

5.2.1.1. Primary Open-Angle Glaucoma (POAG)

5.2.1.2. Secondary Open-Angle Glaucoma

5.2.2. Classification of Close-Angle Glaucoma/Angle-closure glaucoma (ACG)

5.3. Signs and Symptoms of Glaucoma

5.3.1. Signs and Symptoms of Open-Angle Glaucoma

5.3.2. Signs and Symptoms of Closed-angle Glaucoma

5.4. Genes Involved in Glaucoma

5.4.1. Primary Open Angle Glaucoma

5.4.2. Primary Closed Angle Glaucoma (PACG)

5.5. Diagnosis

5.5.1. Diagnosis of Glaucoma

5.5.2. Diagnostic criteria of Angle Closure Glaucoma

5.5.3. Differential Diagnosis of Glaucoma

5.5.4. Diagnostic Algorithm for Glaucoma

5.5.5. Diagnosis of Juvenile Open Angle Glaucoma (JOAG)

5.5.6. Diagnosis of Steroid Induced Glaucoma (SIG)

5.5.7. Primary Glaucoma Preferred Practice Pattern guidelines

5.6. Treatment Algorithm of Glaucoma

5.7. Treatment and Management of Glaucoma

5.7.1. Medicines

5.7.2. Laser treatment

5.7.3. Surgery

5.7.4. Treatment of Primary Open-angle Glaucoma

5.7.5. Treatment for Angle-closure glaucoma (ACG)

5.7.6. Treatment for Juvenile Open Angle Glaucoma (JOAG)

5.7.7. Treatment for Steroid Induced Glaucoma (SIG)

5.8. Treatment and Management Guidelines of Glaucoma

5.8.1. International Council of Ophthalmology Guidelines for Glaucoma Eye Care

5.8.2. Level of evidence and recommendation in medical treatment of PACG.

5.8.3. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation

5.8.4. Primary Open-angle Glaucoma Preferred Practice Pattern guidelines

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

6.3. Total Diagnosed Prevalence of Glaucoma in the 7MM

6.4. Assumptions and Rationales: 7MM

6.5. The United States

6.5.1. Total Diagnosed Prevalence of Glaucoma in the United States

6.5.2. Type-specific Diagnosed Prevalence of Glaucoma in the United States

6.5.3. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma (OAG) in the United States

6.5.4. Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States

6.5.5. Gender-specific Diagnosed Prevalence of Glaucoma in the United States

6.5.6. Age-specific Diagnosed Prevalence of Glaucoma in the United States

6.6. EU5

6.6.1. Total Diagnosed Prevalence of Glaucoma in the EU-5

6.6.2. Type-specific Diagnosed Prevalence of Glaucoma in EU-5

6.6.3. Type-specific Diagnosed Prevalence of Open angle Glaucoma in EU-5

6.6.4. Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in EU-5

6.6.5. Gender-specific Diagnosed Prevalence of Glaucoma in EU-5

6.6.6. Age-specific Diagnosed Prevalence of Glaucoma in EU-5

6.7. Japan

6.7.1. Total Diagnosed Prevalence of Glaucoma in Japan

6.7.2. Type-specific Diagnosed Prevalence of Glaucoma in Japan

6.7.3. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

6.7.4. Type-Specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in Japan

6.7.5. Gender-specific Diagnosed Prevalence of Glaucoma in Japan

6.7.6. Age-specific Diagnosed Prevalence of Glaucoma in Japan

7. Patient Journey

8. Marketed Products

8.1. Key Cross

8.2. Durysta (Bimatoprost SR): Allergan

8.2.1. Product Description

8.2.2. Regulatory Milestones

8.2.3. Clinical Development

8.2.4. Clinical Trials Information

8.2.5. Safety and Efficacy

8.2.6. Product Profile

8.3. Xelpros (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited

8.3.1. Product Description

8.3.2. Regulatory Milestones

8.3.3. Clinical Development

8.3.4. Safety and Efficacy

8.3.5. Product Profile

8.4. Tapcom/DE-111 (Tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.

8.4.1. Product Description

8.4.2. Regulatory Milestones

8.4.3. Clinical Development

8.4.4. Clinical Trials Information

8.4.5. Safety and Efficacy

8.4.6. Product Profile

8.5. Glanatec: D.Western Therapeutics Institute (DWTI)/Kowa Ltd.

8.5.1. Product Description

8.5.2. Regulatory Milestones

8.5.3. Clinical Development

8.5.4. Clinical Trials Information

8.5.5. Safety and Efficacy

8.5.6. Product Profile

8.6. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon

8.6.1. Product Description

8.6.2. Regulatory Milestones

8.6.3. Clinical Development

8.6.4. Clinical Trials Information

8.6.5. Safety and Efficacy

8.6.6. Product Profile

8.7. AILAMIDE/ SJP-0125: Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.

8.7.1. Product Description

8.7.2. Regulatory Milestones

8.7.3. Clinical Development

8.7.4. Product Profile

8.8. Aibeta/SJP-0135: Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.

8.8.1. Product Description

8.8.2. Regulatory Milestones

8.8.3. Clinical Development

8.8.4. Product Profile

8.9. Travatan Z (travoprost ophthalmic solution) 0.004%: Alcon

8.9.1. Product Description

8.9.2. Regulatory Milestones

8.9.3. Clinical Development

8.9.4. Clinical Trials Information

8.9.5. Safety and Efficacy

8.9.6. Product Profile

8.10. Eybelis Ophthalmic Solution 0.002% (DE-117,Omidenepag isopropyl): Santen Pharmaceutical/Ube Industries

8.10.1. Product Description

8.10.2. Regulatory Milestones

8.10.3. Other Developmental Activities

8.10.4. Clinical Development

8.10.5. Clinical Trials Information

8.10.6. Safety and Efficacy

8.10.7. Product Profile

8.11. Vyzulta (BOL-303259-X): Bausch and Lomb

8.11.1. Product Description

8.11.2. Regulatory Milestones

8.11.3. Other Developmental Activities

8.11.4. Clinical Development

8.11.5. Clinical Trials Information

8.11.6. Safety and Efficacy

8.11.7. Product Profile

8.12. Rocklatan: Aerie Pharmaceuticals

8.12.1. Product Description

8.12.2. Regulatory Milestones

8.12.3. Other Developmental Activities

8.12.4. Clinical Development

8.12.5. Clinical Trials Information

8.12.6. Safety and Efficacy

8.12.7. Product Profile

8.13. Rhopressa: Aerie Pharmaceuticals

8.13.1. Product Description

8.13.2. Regulatory Milestones

8.13.3. Other Developmental Activities

8.13.4. Clinical Development

8.13.5. Clinical Trials Information

8.13.6. Safety and Efficacy

8.13.7. Product Profile

8.15. Zioptan (Tafluprost): Merck & Co

8.15.1. Product Description

8.15.2. Regulatory Milestones

8.15.3. Other Developmental Activities

8.15.4. Clinical Development

8.15.5. Clinical Trials Information

8.15.6. Safety and Efficacy

8.15.7. Product Profile

8.16. DuoTrav PQ (Travoprost/timolol): Novartis/ Alcon Research

8.16.1. Product Description

8.16.2. Regulatory Milestones

8.16.3. Other Developmental Activities

8.16.4. Clinical Development

8.16.5. Clinical Trials Information

8.16.6. Safety and Efficacy

8.16.7. Product Profile

8.17. Lumigan 0.01% (bimatoprost ophthalmic solution): Allergan

8.17.1. Product Description

8.17.2. Regulatory Milestones

8.17.3. Other Developmental Activities

8.17.4. Clinical Development

8.17.5. Clinical Trials Information

8.17.6. Safety and Efficacy

8.17.7. Product Profile

9. Emerging Therapies

9.1. Key Cross

9.2. PDP-716 (Brimonidine Tartrate Ophthalmic Suspension): Sun Pharma Advanced Research Company Limited (SPARC)

9.2.1. Product Description

9.2.2. Other Developmental Activities

9.2.3. Clinical Development

9.2.4. Clinical Trials Information

9.2.5. Safety and Efficacy

9.2.6. Product Profile

9.3. Brinzolamide Ophthalmic Solution 1%: Perrigo Company/ Bausch and Lomb

9.3.1. Product Description

9.3.2. Other Developmental Activities

9.3.3. Clinical Development

9.3.4. Clinical Trials Information

9.3.5. Product Profile

9.4. DE-130A (Catioprost): Santen Pharmaceuticals

9.4.1. Product Description

9.4.2. Clinical Development

9.4.3. Clinical Trials Information

9.4.4. Product Profile

9.5. Sepetaprost (DE-126/ONO-9054): Santen Inc. /Ono Pharmaceutical

9.5.1. Product Description

9.5.2. Other Developmental Activities

9.5.3. Clinical Development

9.5.4. Clinical Trials Information

9.5.5. Safety and Efficacy

9.5.6. Product Profile

9.6. NCX-470: Nicox Opthalmics

9.6.1. Product Description

9.6.2. Other Developmental Activities

9.6.3. Clinical Development

9.6.4. Clinical Trials Information

9.6.5. Safety and Efficacy

9.6.6. Product Profile

9.7. Ripasudil Hydrochloride Hydrate/Brimonidine tartrate (K-232): Kowa Company/D. Western Therapeutics Institute

9.7.1. Product Description

9.7.2. Other Developmental Activities

9.7.3. Clinical Development

9.7.4. Clinical Trials Information

9.7.5. Product Profile

9.8. Bamosiran (SLY040012): Sylentis

9.8.1. Product Description

9.8.2. Other Developmental Activities

9.8.3. Clinical Development

9.8.4. Clinical Trials Information

9.8.5. Safety and Efficacy

9.8.6. Product Profile

9.9. Nyxol (Phentolamine Mesylate): Ocuphire Pharma

9.9.1. Product Description

9.9.2. Other Developmental Activities

9.9.3. Clinical Development

9.9.4. Clinical Trials Information

9.9.5. Safety and Efficacy

9.9.6. Product Profile

9.10. ENV515 (Travoprost XR): Envisia Therapeutics

9.10.1. Product Description

9.10.2. Other Developmental Activities

9.10.3. Clinical Development

9.10.4. Clinical Trials Information

9.10.5. Safety and Efficacy

9.10.6. Product Profile

9.11. POLAT-001: Peregrine Ophthalmic

9.11.1. Product Description

9.11.2. Other Developmental Activities

9.11.3. Clinical Development

9.11.4. Clinical Trials Information

9.11.5. Product Profile

9.12. TC-002 Latanoprost Ophthalmic solution: TearClear

9.12.1. Product Description

9.12.2. Other Developmental Activities

9.12.3. Clinical Development

9.12.4. Clinical Trials Information

9.12.5. Product Profile

10. Glaucoma: Seven Major Market Analysis

10.1. Key Findings

10.2. Market Methodology

10.3. Market Size of Glaucoma in the 7MM in USD Million (2019–2032)

10.4. Market Size of Glaucoma by Therapies in the 7MM

10.5. Market Outlook

10.6. Attribute Analysis

10.7. Potential of Current and Emerging therapy

10.8. Key Market Forecast Assumptions

10.9. United States Market Size

10.9.1. Total Market Size of Glaucoma in the United States

10.9.2. Market Size of Glaucoma by Therapies in the United States

10.10. EU-5 Market Size

10.10.1. Total Market size of Glaucoma in EU-5

10.10.2. Market Size of Glaucoma by Therapies in EU-5

10.11. Japan

10.11.1. Total Market size of Glaucoma in Japan

10.11.2. Market Size of Glaucoma by Therapies in Japan

11. KOL Views

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Unmet Needs

16. Reimbursement

17. Appendix

17.1. Report Methodology

17.2. Bibliography

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Glaucoma Market, Epidemiology, and Key Events (2019–2032)

Table 2: Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations

Table 3: Genes associated with the risk of POAG

Table 4: Genes identified in linkage or association with PACG

Table 5: Clinical findings that define patients seen with Angle-Closure disease

Table 6: Differential Diagnosis for Glaucoma

Table 7: The definitions and levels of evidence to rate individual studies

Table 8: Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE

Table 9: Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

Table 10: Primary Closed-Angle Glaucoma Preferred Practice Pattern guidelines

Table 11: Initiating Open-angle Glaucoma Care – International Recommendations

Table 12: Medicines for Glaucoma Care: International Recommendations

Table 13: Initiating Closed-angle Care – International Recommendations

Table 14: Unstable Closed-angle Glaucoma – International Recommendations

Table 15: Level of evidence and recommendation in medical treatment of PACG

Table 16: Level of evidence and recommendation in treatment laser del PACG

Table 17: Level of evidence and recommendation in the surgical treatment of PACG

Table 18: Total Diagnosed Prevalence of Glaucoma in the 7MM (2019–2032)

Table 19: Total Diagnosed Prevalence of Glaucoma in the United State (2019–2032)

Table 20: Type-specific Diagnosed Prevalence of Glaucoma in the US (2019–2032)

Table 21: Type-specific Diagnosed Prevalence of OAG in the United States (2019–2032)

Table 22: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States (2019–2032)

Table 23: Gender-specific Diagnosed Prevalence of Glaucoma in the US (2019–2032)

Table 24: Age-Specific Diagnosed Prevalence of Glaucoma in the United States (2019–2032)

Table 25: Total Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)

Table 26: Type-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)

Table 27: Type-specific Diagnosed Prevalence of OAG in EU-5 (2019–2032)

Table 28: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in EU-5 (2019–2032)

Table 29: Gender-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)

Table 30: Age-Specific Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)

Table 31: Total Diagnosed Prevalence of Glaucoma in Japan (2019–2032)

Table 32: Type-specific Diagnosed Prevalence of Glaucoma, in Japan in ’00 (2019–2032)

Table 33: Type-specific Diagnosed Prevalence of OAG in Japan (2019–2032)

Table 34: Type-specific Diagnosed Prevalence of Secondary OAG in Japan (2019–2032)

Table 35: Gender-specific Diagnosed Prevalence of Glaucoma in Japan (2019–2032)

Table 36: Age-Specific Diagnosed Prevalence of Glaucoma in Japan (2019–2032)

Table 37: Key cross competition- Marketed drugs

Table 38: Durysta (Bimatoprost SR), Clinical Trial Description, 2022

Table 39: Tapcom/DE-111(Tafluprost/ timolol maleate); Clinical Trial Description, 2022

Table 40: Glanatec, Clinical Trial Description, 2022

Table 41: Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, Clinical Trial Description, 2022

Table 42: Travatan Z (travoprost ophthalmic solution) 0.004%, Clinical Trial Description, 2022

Table 43: Eybelis ophthalmic solution (DE-117), Clinical Trial Description, 2022

Table 44: Vyzulta(BOL-303259-X), Clinical Trial Description, 2022

Table 45: Rocklatan(PG324, Netarsudil/Latanoprost 0.02%/0.005%), Clinical Trial Description, 2022

Table 46: Rhopressa(ART-1334), Clinical Trial Description, 2022

Table 47: Zioptan (Tafluprost), Clinical Trial Description, 2022

Table 48: DuoTrav, Clinical Trial Description, 2022

Table 49: Lumigan (Bimatoprost 0.01% Ophthalmic Solution) ,Clinical Trial Description, 2022

Table 50: Key-cross competition - emerging drugs

Table 51: PDP–716 (Brimonidine Tartrate Ophthalmic Suspension), Clinical Trial Description, 2022

Table 52: Brinzolamide Ophthalmic Suspension 1%, Clinical Trial Description, 2022

Table 53: DE-130A (Catioprost), Clinical Trial Description, 2022

Table 54: Sepetaprost (DE-126/ ONO-9054), Clinical Trial Description, 2022

Table 55: NCX 470, Clinical Trial Description, 2022

Table 56: K-232, Clinical Trial Description, 2022

Table 57: Bamosiran (SLY040012), Clinical Trial Description, 2022

Table 58: Nyxol (Phentolamine Mesylate), Clinical Trial Description, 2022

Table 59: ENV-515 (Travoprost), Clinical Trial Description, 2022

Table 60: POLAT-001, Clinical Trial Description, 2022

Table 61: TC-002(Latanoprost ophthalmic solution), Clinical Trial Description, 2022

Table 62: Market Size of Glaucoma in the 7MM in USD Million (2019–2032)

Table 63: Market Size of Glaucoma by therapies in the 7MM, in USD Million (2019–2032)

Table 64: Currently Prescribed Classes and their Side-Effects

Table 65: Key Market Forecast Assumptions for Vyzulta

Table 66: Key Market Forecast Assumptions for Rhopressa/Rhokiinsa

Table 67: Key Market Forecast Assumptions for Roclanda/Rocklatan

Table 68: Key Market Forecast Assumptions for Xelpros

Table 69: Key Market Forecast Assumptions for DURYSTA (bimatoprost implant)

Table 70: Key Market Forecast Assumptions for EYBELIS/Omidenepag isopropyl/DE-117

Table 71: Key Market Forecast Assumptions for PDP-716

Table 72: Key Market Forecast Assumptions for DE-130A

Table 73: Key Market Forecast Assumptions for Sepetaprost (DE-126/ONO-9054)

Table 74: Key Market Forecast Assumptions for NCX 470

Table 75: Key Market Forecast Assumptions for Nyxol

Table 76: Key Market Forecast Assumptions for K-232 (Ripasudil/Brimonidine)

Table 77: Market Size of Glaucoma in the United States in USD Million (2019–2032)

Table 78: Market Size of Glaucoma by therapies in the United States, in USD Million (2019–2032)

Table 79: Germany Market Size of Glaucoma in USD Million (2019–2032)

Table 80: Market Size of Glaucoma by therapies in EU-5 in USD Million (2019–2032)

Table 81: Japan Market Size of Glaucoma in USD Million (2019–2032)

Table 82: Market Size of Glaucoma by therapies in Japan, in USD Million (2019–2032)

List of Figures

Figure 1: Classification of Glaucoma

Figure 2: Classification of Open-Angle Glaucoma

Figure 3: Risk Factors Associated with POAG

Figure 4: Glaucoma classification and subtypes.

Figure 5: Symptoms of Open-Angle Glaucoma

Figure 6: Symptoms of Closed-angle Glaucoma

Figure 7: Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by an MYOC mutation

Figure 8: Diagnosis of Glaucoma

Figure 9: Glaucoma Assessment (Optic Nerve)

Figure 10: Evaluation of a glaucoma suspect (open-angle glaucoma)

Figure 11: Treatment of primary open-angle glaucoma: Medical treatment

Figure 12: Treatment Algorithm for Open-Angle Glaucoma

Figure 13: Diagnostic and management algorithm for patient with JOAG

Figure 14: Treatment of Glaucoma

Figure 15: Total Diagnosed Prevalence of Glaucoma in the 7MM (2019–2032)

Figure 16: Total Diagnosed Prevalence of Glaucoma in the United States (2019–2032)

Figure 17: Type-specific Diagnosed Prevalence of Glaucoma in the US (2019–2032)

Figure 18: Type-specific Diagnosed Prevalence of OAG in the United States (2019–2032)

Figure 19: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States (2019–2032)

Figure 20: Gender-specific Diagnosed Prevalence of Glaucoma in the US (2019–2032)

Figure 21 Age-Specific Diagnosed Prevalence of Glaucoma in the United States (2019–2032)

Figure 22: Total Diagnosed Prevalence of Glaucoma in the EU-5 (2019–2032)

Figure 23: Type-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)

Figure 24: Type-specific Diagnosed Prevalence of OAG in EU-5 (2019–2032)

Figure 25: Type-specific Diagnosed Prevalence of secondary Open-Angle Glaucoma in EU-5 (2019–2032)

Figure 26: Gender-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)

Figure 27 Age-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)

Figure 28: Total Diagnosed Prevalence of Glaucoma in Japan (2019–2032)

Figure 29: Type-specific Diagnosed Prevalence of Glaucoma in Japan (2019–2032)

Figure 30: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2019–2032)

Figure 31: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2019–2032)

Figure 32: Gender-specific Diagnosed Prevalence of Glaucoma in Japan (2019–2032)

Figure 33: Age-specific Diagnosed Prevalence of Glaucoma in Japan (2019–2032)

Figure 34: Market Size of Glaucoma in the 7MM in USD Million (2019–2032)

Figure 35: Seven Major Market Size of Glaucoma by Therapies in the 7MM, in USD Million (2019–2032)

Figure 36: Market Size of Glaucoma in the US, USD Millions (2019–2032)

Figure 37: Market Size of Glaucoma by therapies in the United States, in USD Million (2019–2032)

Figure 38: Market Size of Glaucoma in EU-5, USD Million (2019–2032)

Figure 39: EU-5 Market Size of Glaucoma by Therapies in USD Million (2019–2032)

Figure 40: Market Size of Glaucoma in Japan, USD Million (2019–2032)

Figure 41:Japan Market Size of Glaucoma by Therapies in USD Million (2019–2032)

Figure 42: Market Drivers

Figure 43: Market Barriers

Figure 44: Unmet Needs

Allergan
Sun Pharma Advanced Research Company Limited
Santen Pharmaceutical Co., Ltd.
D.Western Therapeutics Institute (DWTI)
Kowa Ltd.
Alcon
Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.
TearClear
Peregrine Ophthalmic
Envisia Therapeutics
Ocuphire Pharma
Sylentis
Nicox Opthalmics
Santen Pharmaceuticals
Perrigo Company
Bausch and Lomb
Ono Pharmaceutical
Novartis
Merck & Co
Aerie Pharmaceuticals
Ube Industries

 

Forward to Friend

Need A Quote